Cervical Cancer Cin Grade Clinical Trial
Official title:
Experimentation of New Organizational Models of Cervical Cancer Screening Programs, Upon the Use of HPV Test as First Level: Evaluation of the Methodologies Proposed of the Use of Self-sampling Devices to Recover Non-responders.
The opportunity of a home, self-collected sample, opens the chance to remove some of the
barriers that may discourage women from participating to screening programmes or performing
HPV (Human Papilloma Virus)-test. Self-sampling is less time consuming and invasive as
compared with tests performed at a clinic. It allows for privacy, reduces discomfort and
women know nobody would have to handle their body.
Study hypothesis: The use of a self-sampler may increase the recovery of non-responders
women at cervical cancer screening.
In a previous trial (ISRCTN96071600) the investigators tested on 2400 women, compliance with
self sampler device (PantaRhei Devices, Zeist, the Netherlands).
With this study the investigators analyze the response to two channels of transmission of
the device (a model of device easier, and less expensive than the previous), such as
screening for colon cancer.
The shipment of the device at home and taking on a local pharmacy. Involving 15000 women
non-responders to previous calls in five different screening programs in Italy (Rome,
Bologna, Abruzzo region, Molise region, Veneto region).
;
Observational Model: Cohort, Time Perspective: Prospective